Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 23, 2018
23 Mar 2018 KING OF PRUSSIA, Pa. – March 23, 2018 – CSL Behring, a global biotherapeutics leader, today announced the initiation of the AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes...
-
Mar 20, 2018Global biotech leader rated at no. 42 for patient focus, innovation and sustainable growth
20 Mar 2018 KING OF PRUSSIA, Pa. – March 20, 2018 – Forbes has named global biotechnology leader CSL Limited among the world’s Top 50 employers, landing at no. 42 in the business media’s...
-
Mar 17, 2018
Vifor Pharma gives Zeria exclusive rights to develop and market Veltassa® in Japan Potential of Veltassa® further validated with expansion into Japanese market Deal expands cardio-renal network...
-
Mar 16, 2018First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP
16 Mar 2018 KING OF PRUSSIA, Pa. – March 16, 2018 – Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) approved Hizentra® (Immune...
-
Mar 15, 2018
IN 2017 VIFOR PHARMA RECORDED A STRONG FINANCIAL PERFORMANCE DRIVEN BY ITS THREE MEDIUM-TERM STRATEGIC GROWTH-DRIVERS AND THE SUCCESSFUL DIVESTITURE OF ITS NON-CORE WHOLESALE/RETAIL PHARMACY...
-
Mar 15, 2018First and only subcutaneous immunoglobulin approved for the treatment of CIDP, based on findings from the largest controlled clinical CIDP study
15 Mar 2018 HATTERSHEIM, Germany – 15 March 2018 – Global biotherapeutics leader CSL Behring today announced that the European Commission (EC) has granted marketing authorization for...
-
Mar 15, 2018Life Sciences Pennsylvania recognized CSL Behring’s commitment to patients for its novel subcutaneous C1 esterase inhibitor, HAEGARDA®, to prevent swelling caused by the rare genetic disorder
15 Mar 2018 KING OF PRUSSIA, Pa. – March 15, 2018 – Imagine not knowing when you might experience unpredictable, severe and painful swelling without warning in different parts of your body,...
-
Mar 13, 2018- Industry’s role in ensuring access to medicine is an imperative, not an afterthought - Patient engagement is a key driver to strengthen access
13 Mar 2018 BARCELONA, SPAIN – March 13, 2018 – In a keynote address on patients’ access to medicines at the eyeforpharma Barcelona summit, CSL Chief Executive Officer and Managing Director...
-
Mar 8, 2018
Updated label may allow for increased dosing flexibility for patients with hyperkalaemia Label update effective immediately in the US THE UNITED STATES (US) FOOD AND DRUG ADMINISTRATION (FDA) HAS...
-
Feb 8, 2018
VIFOR PHARMA ANNOUNCED TODAY THAT VIT-2763, THE FIRST-EVER ORAL FERROPORTIN INHIBITOR FOR PREVENTING IRON OVERLOAD WILL ENTER CLINICAL DEVELOPMENT WITH A PHASE-I STUDY AT THE BEGINNING OF MARCH...